Noninferiority Trials: A Critical Framework for Comparative Efficacy Assessment in Cardiovascular Research (Motivated by the RE-LY Study on Dabigatran versus Warfarin in Atrial Fibrillation by Connolly et al.)

Noninferiority trials play a central role in contemporary cardiovascular research, particularly when established therapies already provide substantial clinical benefit and the use of placebo controls is unethical. Rather than demonstrating superiority, these designs assess whether a new intervention preserves an acceptable level of efficacy compared with a proven standard while offering advantages in safety, tolerability, or convenience. This report presents a critical framework for understanding the rationale, design, interpretation, and limitations of noninferiority trials, using the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) study comparing dabigatran with warfarin in atrial fibrillation as a motivating example. Key methodological elements are examined, including the justification of noninferiority margins, the importance of high-quality and complete datasets, and the complementary roles of intention-to-treat and per-protocol analyses. Through detailed discussion of efficacy, safety, and subgroup findings from RE-LY, the report illustrates how noninferiority designs can both safeguard patient outcomes and enable therapeutic innovation. Strengths and limitations of this approach are critically assessed, alongside future directions incorporating adaptive, pragmatic, and Bayesian methods. Overall, the report highlights noninferiority trials as an essential tool for advancing evidence-based cardiovascular care in settings of therapeutic equivalence.